<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755831</url>
  </required_header>
  <id_info>
    <org_study_id>NMCSD.2016.0029</org_study_id>
    <nct_id>NCT02755831</nct_id>
  </id_info>
  <brief_title>Targeted CPAP Therapy for Obstructive Sleep Apnea in Pregnancy</brief_title>
  <official_title>Randomized Controlled Trial for a Sleep Study and Targeted CPAP Therapy for Obstructive Sleep Apnea to Reduce the Incidence Adverse Pregnancy Related Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Naval Medical Center, San Diego</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United States Naval Medical Center, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized controlled trial. Pregnant women in early pregnancy will be
      randomized to either the Sleep Study + CPAP (Continuous Positive Airway Pressure Therapy)
      group or to a Standard Prenatal Care group. Subjects in the Sleep Study + CPAP group will
      complete a sleep study (WatchPAT-200, Itamar Medical, Inc.) and have CPAP initiated if the
      Apnea Hypopnea Index (AHI) ≥5 as indicated, in early and late pregnancy, whereas the other
      group will receive standard prenatal care. All subjects will complete a sleep study again
      between 8 to 12 weeks postpartum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective/Hypothesis: The purpose of this study is to determine if parturients identified as
      high risk for obstructive sleep apnea (OSA; defined as an apnea hypopnea index [AHI] ≥5
      events/hour) who are randomized to receive an unattended sleep study during early and late
      pregnancy (early = between 6 and 16 weeks; late = between 27 and 33 weeks) plus initiation of
      CPAP therapy if the AHI ≥5 events/hour and standard prenatal care have a decreased incidence
      of adverse pregnancy outcomes (defined as a composite variable which includes gestational
      hypertension, preeclampsia, eclampsia, gestational diabetes, preterm birth, low birth weight,
      or stillbirth) at the time of delivery when compared to a group who receives standard
      prenatal care only (no sleep study and CPAP initiation). At 8 to 12 months postpartum
      subjects in both groups will complete a sleep study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">October 14, 2019</completion_date>
  <primary_completion_date type="Actual">October 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Pregnancy Outcomes</measure>
    <time_frame>time of delivery</time_frame>
    <description>Number of participants with adverse pregnancy outcomes (composite outcome includes: gestational hypertension, preeclampsia, eclampsia, gestational diabetes, preterm delivery, low birth weight, or stillbirth)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Obstructive Sleep Apnea (OSA) in Early Pregnancy - Treatment Group Only (6-16 Weeks)</measure>
    <time_frame>early pregnancy (6-16 weeks)</time_frame>
    <description>Incidence of OSA severity in early pregnancy (6-16 weeks) in treatment group only. Data were not collected for Control group at this time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of OSA in Late Pregnancy- Treatment Group Only (27-33 Weeks)</measure>
    <time_frame>27-33 weeks</time_frame>
    <description>Incidence and severity of OSA in late pregnancy- treatment group only (27-33 weeks). Data were not collected for Control group at this time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of OSA at 8 to 12 Weeks Postpartum in Treatment and Control Group</measure>
    <time_frame>8-12 weeks postpartum</time_frame>
    <description>Incidence and severity of OSA at 8 to 12 weeks postpartum in treatment and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Costs at Time of Delivery</measure>
    <time_frame>Hospital costs at time of delivery</time_frame>
    <description>Hospital costs at time of delivery in treatment and control group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Sleep Study + CPAP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Prenatal Care group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
    <arm_group_label>Sleep Study + CPAP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-natal care</intervention_name>
    <description>Standard Pre-Natal Care</description>
    <arm_group_label>Standard Prenatal Care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. At least one of the following risk factors for OSA: prepregnancy BMI ≥ 30kg/m2,
             chronic hypertension, pregestational diabetes, twin gestation, or a history of prior
             pregnancy affected by: preeclampsia, eclampsia or fetal growth restriction.

          2. Between 6 and 16 weeks gestation at time of enrollment.

        Exclusion Criteria

          1. Current diagnosis and treatment of OSA.

          2. Patient refusal to randomization.

          3. Permanent Pacemaker (interfere with WATCHPAT sleep study).

          4. Currently taking alpha blockers or nitrates (interfere with WATCHPAT sleep study).

          5. Coronary artery disease or congestive heart failure or cardiomyopathy.

          6. Not delivering and completing their postpartum visit at Naval Medical Center San Diego
             (NMCSD).

          7. Inability to read or understand the consent.

          8. &lt;18 years of age.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis L Spence, PhD</last_name>
    <role>Study Director</role>
    <affiliation>United States Naval Medical Center, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Poyares D, Guilleminault C, Hachul H, Fujita L, Takaoka S, Tufik S, Sass N. Pre-eclampsia and nasal CPAP: part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP intervention. Sleep Med. 2007 Dec;9(1):15-21. Epub 2007 Jul 20.</citation>
    <PMID>17644475</PMID>
  </reference>
  <reference>
    <citation>Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000 Apr 12;283(14):1829-36. Erratum in: JAMA 2002 Oct 23-30;288(16):1985.</citation>
    <PMID>10770144</PMID>
  </reference>
  <reference>
    <citation>Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, Stubbs R, Hla KM. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008 Aug;31(8):1071-8.</citation>
    <PMID>18714778</PMID>
  </reference>
  <reference>
    <citation>Young T, Palta M, Dempsey J, Peppard PE, Nieto FJ, Hla KM. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ. 2009 Aug;108(5):246-9.</citation>
    <PMID>19743755</PMID>
  </reference>
  <reference>
    <citation>Memtsoudis SG, Sun X, Chiu YL, Nurok M, Stundner O, Pastores SM, Mazumdar M. Utilization of critical care services among patients undergoing total hip and knee arthroplasty: epidemiology and risk factors. Anesthesiology. 2012 Jul;117(1):107-16. doi: 10.1097/ALN.0b013e31825afd36.</citation>
    <PMID>22634871</PMID>
  </reference>
  <reference>
    <citation>Luque-Fernandez MA, Bain PA, Gelaye B, Redline S, Williams MA. Sleep-disordered breathing and gestational diabetes mellitus: a meta-analysis of 9,795 participants enrolled in epidemiological observational studies. Diabetes Care. 2013 Oct;36(10):3353-60. doi: 10.2337/dc13-0778.</citation>
    <PMID>24065843</PMID>
  </reference>
  <reference>
    <citation>Ding XX, Wu YL, Xu SJ, Zhang SF, Jia XM, Zhu RP, Hao JH, Tao FB. A systematic review and quantitative assessment of sleep-disordered breathing during pregnancy and perinatal outcomes. Sleep Breath. 2014 Dec;18(4):703-13. doi: 10.1007/s11325-014-0946-4. Epub 2014 Feb 12. Review.</citation>
    <PMID>24519711</PMID>
  </reference>
  <reference>
    <citation>Pamidi S, Pinto LM, Marc I, Benedetti A, Schwartzman K, Kimoff RJ. Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2014 Jan;210(1):52.e1-52.e14. doi: 10.1016/j.ajog.2013.07.033. Epub 2013 Aug 2. Review.</citation>
    <PMID>23911687</PMID>
  </reference>
  <reference>
    <citation>Louis J, Auckley D, Miladinovic B, Shepherd A, Mencin P, Kumar D, Mercer B, Redline S. Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women. Obstet Gynecol. 2012 Nov;120(5):1085-92. doi: 10.1097/AOG.0b013e31826eb9d8.</citation>
    <PMID>23090526</PMID>
  </reference>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology. 2014 Feb;120(2):268-86. doi: 10.1097/ALN.0000000000000053. Review.</citation>
    <PMID>24346178</PMID>
  </reference>
  <reference>
    <citation>Ankichetty SP, Angle P, Joselyn AS, Chinnappa V, Halpern S. Anesthetic considerations of parturients with obesity and obstructive sleep apnea. J Anaesthesiol Clin Pharmacol. 2012 Oct;28(4):436-43. doi: 10.4103/0970-9185.101895.</citation>
    <PMID>23225920</PMID>
  </reference>
  <reference>
    <citation>Reutrakul S, Zaidi N, Wroblewski K, Kay HH, Ismail M, Ehrmann DA, Van Cauter E. Interactions between pregnancy, obstructive sleep apnea, and gestational diabetes mellitus. J Clin Endocrinol Metab. 2013 Oct;98(10):4195-202. doi: 10.1210/jc.2013-2348. Epub 2013 Aug 21.</citation>
    <PMID>23966237</PMID>
  </reference>
  <reference>
    <citation>Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 Jun 15;5(3):263-76.</citation>
    <PMID>19960649</PMID>
  </reference>
  <reference>
    <citation>Louis JM, Mogos MF, Salemi JL, Redline S, Salihu HM. Obstructive sleep apnea and severe maternal-infant morbidity/mortality in the United States, 1998-2009. Sleep. 2014 May 1;37(5):843-9. doi: 10.5665/sleep.3644.</citation>
    <PMID>24790262</PMID>
  </reference>
  <reference>
    <citation>Facco FL, Ouyang DW, Zee PC, Grobman WA. Sleep disordered breathing in a high-risk cohort prevalence and severity across pregnancy. Am J Perinatol. 2014 Nov;31(10):899-904. doi: 10.1055/s-0033-1363768. Epub 2014 Feb 10.</citation>
    <PMID>24515622</PMID>
  </reference>
  <reference>
    <citation>Pien GW, Pack AI, Jackson N, Maislin G, Macones GA, Schwab RJ. Risk factors for sleep-disordered breathing in pregnancy. Thorax. 2014 Apr;69(4):371-7. doi: 10.1136/thoraxjnl-2012-202718. Epub 2013 Nov 21.</citation>
    <PMID>24262432</PMID>
  </reference>
  <reference>
    <citation>Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342. Epub 2013 Apr 14.</citation>
    <PMID>23589584</PMID>
  </reference>
  <reference>
    <citation>Morgenthaler TI, Aurora RN, Brown T, Zak R, Alessi C, Boehlecke B, Chesson AL Jr, Friedman L, Kapur V, Maganti R, Owens J, Pancer J, Swick TJ; Standards of Practice Committee of the AASM; American Academy of Sleep Medicine. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep. 2008 Jan;31(1):141-7.</citation>
    <PMID>18220088</PMID>
  </reference>
  <reference>
    <citation>Guilleminault C, Palombini L, Poyares D, Takaoka S, Huynh NT, El-Sayed Y. Pre-eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk-factors for pre-eclampsia: preliminary findings. Sleep Med. 2007 Dec;9(1):9-14. Epub 2007 Jul 17.</citation>
    <PMID>17644420</PMID>
  </reference>
  <reference>
    <citation>Whitehead C, Tong S, Wilson D, Howard M, Walker SP. Treatment of early-onset preeclampsia with continuous positive airway pressure. Obstet Gynecol. 2015 May;125(5):1106-9. doi: 10.1097/AOG.0000000000000508.</citation>
    <PMID>25774926</PMID>
  </reference>
  <reference>
    <citation>Facco F. Sleep-disordered breathing in pregnancy: a brief summary of current knowledge. BJOG. 2014 Dec;121(13):1694. doi: 10.1111/1471-0528.12888. Epub 2014 May 30.</citation>
    <PMID>24889020</PMID>
  </reference>
  <reference>
    <citation>Izci-Balserak B, Pien GW. Sleep-disordered breathing and pregnancy: potential mechanisms and evidence for maternal and fetal morbidity. Curr Opin Pulm Med. 2010 Nov;16(6):574-82. doi: 10.1097/MCP.0b013e32833f0d55. Review.</citation>
    <PMID>20859210</PMID>
  </reference>
  <reference>
    <citation>Volná J, Kemlink D, Kalousová M, Vávrová J, Majerová V, Mestek O, Svarcová J, Sonka K, Zima T. Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. Med Sci Monit. 2011 Sep;17(9):CR491-7.</citation>
    <PMID>21873945</PMID>
  </reference>
  <reference>
    <citation>Lyall F, Robson SC, Bulmer JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. Hypertension. 2013 Dec;62(6):1046-54. doi: 10.1161/HYPERTENSIONAHA.113.01892. Epub 2013 Sep 23.</citation>
    <PMID>24060885</PMID>
  </reference>
  <reference>
    <citation>Fung AM, Wilson DL, Lappas M, Howard M, Barnes M, O'Donoghue F, Tong S, Esdale H, Fleming G, Walker SP. Effects of maternal obstructive sleep apnoea on fetal growth: a prospective cohort study. PLoS One. 2013 Jul 24;8(7):e68057. doi: 10.1371/journal.pone.0068057. Print 2013.</citation>
    <PMID>23894293</PMID>
  </reference>
  <reference>
    <citation>Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997 Sep;20(9):705-6.</citation>
    <PMID>9406321</PMID>
  </reference>
  <reference>
    <citation>Reid J, Glew RA, Skomro R, Fenton M, Cotton D, Olatunbosun F, Gjevre J, Guilleminault C. Sleep disordered breathing and gestational hypertension: postpartum follow-up study. Sleep. 2013 May 1;36(5):717-721B. doi: 10.5665/sleep.2634.</citation>
    <PMID>23633754</PMID>
  </reference>
  <reference>
    <citation>Hermes W, Tamsma JT, Grootendorst DC, Franx A, van der Post J, van Pampus MG, Bloemenkamp KW, Porath M, Mol BW, de Groot CJ. Cardiovascular risk estimation in women with a history of hypertensive pregnancy disorders at term: a longitudinal follow-up study. BMC Pregnancy Childbirth. 2013 Jun 4;13:126. doi: 10.1186/1471-2393-13-126.</citation>
    <PMID>23734952</PMID>
  </reference>
  <reference>
    <citation>Chen YH, Kang JH, Lin CC, Wang IT, Keller JJ, Lin HC. Obstructive sleep apnea and the risk of adverse pregnancy outcomes. Am J Obstet Gynecol. 2012 Feb;206(2):136.e1-5. doi: 10.1016/j.ajog.2011.09.006. Epub 2011 Sep 16.</citation>
    <PMID>22000892</PMID>
  </reference>
  <reference>
    <citation>Facco FL, Ouyang DW, Zee PC, Grobman WA. Development of a pregnancy-specific screening tool for sleep apnea. J Clin Sleep Med. 2012 Aug 15;8(4):389-94. doi: 10.5664/jcsm.2030.</citation>
    <PMID>22893769</PMID>
  </reference>
  <reference>
    <citation>Hedner J, Pillar G, Pittman SD, Zou D, Grote L, White DP. A novel adaptive wrist actigraphy algorithm for sleep-wake assessment in sleep apnea patients. Sleep. 2004 Dec 15;27(8):1560-6.</citation>
    <PMID>15683148</PMID>
  </reference>
  <reference>
    <citation>Penzel T, Kesper K, Pinnow I, Becker HF, Vogelmeier C. Peripheral arterial tonometry, oximetry and actigraphy for ambulatory recording of sleep apnea. Physiol Meas. 2004 Aug;25(4):1025-36.</citation>
    <PMID>15382839</PMID>
  </reference>
  <reference>
    <citation>Ahmadi N, Chung SA, Gibbs A, Shapiro CM. The Berlin questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. Sleep Breath. 2008 Mar;12(1):39-45.</citation>
    <PMID>17684781</PMID>
  </reference>
  <reference>
    <citation>Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May;108(5):812-21. doi: 10.1097/ALN.0b013e31816d83e4.</citation>
    <PMID>18431116</PMID>
  </reference>
  <reference>
    <citation>Rogers AE, Caruso CC, Aldrich MS. Reliability of sleep diaries for assessment of sleep/wake patterns. Nurs Res. 1993 Nov-Dec;42(6):368-72.</citation>
    <PMID>8247821</PMID>
  </reference>
  <reference>
    <citation>Haythornthwaite JA, Hegel MT, Kerns RD. Development of a sleep diary for chronic pain patients. J Pain Symptom Manage. 1991 Feb;6(2):65-72.</citation>
    <PMID>2007794</PMID>
  </reference>
  <reference>
    <citation>Finkel KJ, Searleman AC, Tymkew H, Tanaka CY, Saager L, Safer-Zadeh E, Bottros M, Selvidge JA, Jacobsohn E, Pulley D, Duntley S, Becker C, Avidan MS. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. Sleep Med. 2009 Aug;10(7):753-8. doi: 10.1016/j.sleep.2008.08.007. Epub 2009 Jan 30.</citation>
    <PMID>19186102</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>October 14, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>United States Naval Medical Center, San Diego</investigator_affiliation>
    <investigator_full_name>CAPT Dennis Spence, NC, USN, PhD, CRNA</investigator_full_name>
    <investigator_title>Anesthesia Nurse</investigator_title>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>pregnancy</keyword>
  <keyword>adverse pregnancy outcomes</keyword>
  <keyword>continuous positive airway pressure</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>gestational diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to submit manuscripts to appropriate journals and present data at appropriate conferences</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02755831/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment. There were 714 women assessed for eligibility with N = 193 enrolled; n = 100 allocated to treatment group and n = 93 to the control group. In the treatment group there were n = 3 and n = 3 in the control group, respectively, loss to follow-up. The final analysis included n = 97 in the treatment group and n = 90 in the control group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sleep Study + CPAP Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
        </group>
        <group group_id="P2">
          <title>Standard Prenatal Care Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sleep Study + CPAP Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
        </group>
        <group group_id="B2">
          <title>Standard Prenatal Care Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="4.8"/>
                    <measurement group_id="B2" value="28.8" spread="5.2"/>
                    <measurement group_id="B3" value="29" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Pregnancy BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="7"/>
                    <measurement group_id="B2" value="33.3" spread="6.8"/>
                    <measurement group_id="B3" value="33.9" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Pregnancy Outcomes</title>
        <description>Number of participants with adverse pregnancy outcomes (composite outcome includes: gestational hypertension, preeclampsia, eclampsia, gestational diabetes, preterm delivery, low birth weight, or stillbirth)</description>
        <time_frame>time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleep Study + CPAP Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
          </group>
          <group group_id="O2">
            <title>Standard Prenatal Care Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Pregnancy Outcomes</title>
          <description>Number of participants with adverse pregnancy outcomes (composite outcome includes: gestational hypertension, preeclampsia, eclampsia, gestational diabetes, preterm delivery, low birth weight, or stillbirth)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher's Exact Test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Obstructive Sleep Apnea (OSA) in Early Pregnancy - Treatment Group Only (6-16 Weeks)</title>
        <description>Incidence of OSA severity in early pregnancy (6-16 weeks) in treatment group only. Data were not collected for Control group at this time point.</description>
        <time_frame>early pregnancy (6-16 weeks)</time_frame>
        <population>Friedman’s test was used to analyze differences in sleep study results at the three time points in experimental group. If significant differences are found in sleep study results a post hoc Wilcoxon Ranked Sign test will be used to compare differences at individual time points. Data were not collected for Control group at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Sleep Study + CPAP Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Obstructive Sleep Apnea (OSA) in Early Pregnancy - Treatment Group Only (6-16 Weeks)</title>
          <description>Incidence of OSA severity in early pregnancy (6-16 weeks) in treatment group only. Data were not collected for Control group at this time point.</description>
          <population>Friedman’s test was used to analyze differences in sleep study results at the three time points in experimental group. If significant differences are found in sleep study results a post hoc Wilcoxon Ranked Sign test will be used to compare differences at individual time points. Data were not collected for Control group at this time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mild OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>moderate OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>severe OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>Friedman test</method>
            <method_desc>Friedman’s test was used to analyze differences with a post hoc Wilcoxon Ranked Sign test to compare differences at individual time points.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of OSA in Late Pregnancy- Treatment Group Only (27-33 Weeks)</title>
        <description>Incidence and severity of OSA in late pregnancy- treatment group only (27-33 weeks). Data were not collected for Control group at this time point</description>
        <time_frame>27-33 weeks</time_frame>
        <population>Incidence and Severity of OSA in Late Pregnancy. Outcome data was only collected in the treatment group. Data were not collected for Control group at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Sleep Study + CPAP Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of OSA in Late Pregnancy- Treatment Group Only (27-33 Weeks)</title>
          <description>Incidence and severity of OSA in late pregnancy- treatment group only (27-33 weeks). Data were not collected for Control group at this time point</description>
          <population>Incidence and Severity of OSA in Late Pregnancy. Outcome data was only collected in the treatment group. Data were not collected for Control group at this time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman</method>
            <method_desc>Friedman’s test was used to analyze differences with a post hoc Wilcoxon Ranked Sign test to compare differences at individual time points.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of OSA at 8 to 12 Weeks Postpartum in Treatment and Control Group</title>
        <description>Incidence and severity of OSA at 8 to 12 weeks postpartum in treatment and control group.</description>
        <time_frame>8-12 weeks postpartum</time_frame>
        <population>Incidence and Severity of OSA at 8-12 weeks postpartum. This is the only time point in which both groups completed sleep studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Sleep Study + CPAP Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
          </group>
          <group group_id="O2">
            <title>Standard Prenatal Care Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of OSA at 8 to 12 Weeks Postpartum in Treatment and Control Group</title>
          <description>Incidence and severity of OSA at 8 to 12 weeks postpartum in treatment and control group.</description>
          <population>Incidence and Severity of OSA at 8-12 weeks postpartum. This is the only time point in which both groups completed sleep studies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mild OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe OSA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman’s test was used to analyze differences with a post hoc Wilcoxon Ranked Sign test to compare differences in treatment group only.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Costs at Time of Delivery</title>
        <description>Hospital costs at time of delivery in treatment and control group.</description>
        <time_frame>Hospital costs at time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleep Study + CPAP Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
          </group>
          <group group_id="O2">
            <title>Standard Prenatal Care Group</title>
            <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Costs at Time of Delivery</title>
          <description>Hospital costs at time of delivery in treatment and control group.</description>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12185" lower_limit="11155" upper_limit="13215"/>
                    <measurement group_id="O2" value="12607" lower_limit="11210" upper_limit="14004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>T-test used to compare mean difference in hospital costs at time of delivery.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse data collected after time of enrollment to study completion ( February 20, 2017 - October 14, 2019). Subjects were enrolled starting at 6 to 12 weeks gestation and were followed until approximately 3 months postpartum (8 to 12 weeks postpartum).</time_frame>
      <desc>No adverse events occurred</desc>
      <group_list>
        <group group_id="E1">
          <title>Sleep Study + CPAP Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
CPAP: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea</description>
        </group>
        <group group_id="E2">
          <title>Standard Prenatal Care Group</title>
          <description>Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
Pre-natal care: Standard Pre-Natal Care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CAPTAIN Dennis Spence, NC, USN, PhD, CRNA</name_or_title>
      <organization>Naval Medical Center San Diego</organization>
      <phone>6199161680</phone>
      <email>dennis.l.spence.mil@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

